Pharma Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and MolMed. Can you please give our readers a brief rundown of the history of MolMed since its foundation in 1996?…
Pharma Mario Marazziti, President of the Italian XII Social Affairs Commission, discusses new legislation relating to clinical risk, the effects of the 2014 Pact for Health, and the efficiency of Italian healthcare in general. You were recently highly instrumental in the passing of new legislation relating to clinical risk. Could you…
Pharma Eclectic demographics, rapid patient recruitment, and a burgeoning population with a gradient of disease profiles—these seem to be the fundamentals truly driving growth in South Africa’s clinical trial industry. However, without the presence of proper mechanisms to arbitrate between regulators and researchers, the sustained growth of this industry may very…
Pharma Fresenius Kabi’s general manager for the MENA region discusses evolving attitudes towards clinical nutrition for critically ill patients and Egypt’s positioning as a knowledge center and source of medical professionals at the regional level. Fresenius is the undisputed provider of critical care worldwide. What products do you offer in Egypt…
Pharma Pharmaceuticals Mauritius’s economic stability, genetic diversity, cost competitiveness, and location make it a perfect location for clinical research; a fact the state is now actively promoting. A further vision of the Mauritian government is to transform the island into a medical hub for clinical research. Besides political and economic stability, a number of…
Pharma Pier Mannuccio Mannucci, Scientific Director of the Policlinico Foundation, describes some of the challenges the scientific community currently faces in Italy and what actions need to be taken to overcome these. He goes on to discuss the main objectives of the foundation and how the recent restructuring will provide better…
Pharma While functional outsourcing may be common for companies seeking services from CROs, Medpace believes that their robust, physician-led, full-service business model is the most efficient way to conduct clinical research. Clinical Trial Manager, Patrick Winkler, and Senior Business Development Executive, Geoffrey Bilon, share the service offerings of Medpace, as well…
Pharma Peter Schoevers, CEO and co-founder of Julius Clinical, explains how this innovative and thriving organization allies the academic strength of an ARO with the business-oriented leadership of a CRO. Julius Clinical aims to become the partner of choice for the pharmaceutical industry by strengthening clinical trial credibility, enhancing its quality…
Pharma Click here to read more articles and interviews from Peru, and to download the latest free pharma report on the country.
Pharma Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented neo-epitopes combination, its plans to break into the immuno-oncology domain and its perspectives on the French regulatory and biotech environments, and emphasizes…
pharma Professor Paul Smits, Dean and Vice Chairman of Radboud University Medical Center in the Netherlands, shares his insights into the strengths of the country’s research climate and the challenges posed by the increasingly high cost of innovative drugs on the healthcare budget. Prof. Smits highlights the benefits that could be…
Pharma Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel Chimos’ emphasis on innovation and R&D and discusses the promising orphan drug the company is in the process of developing. He…
See our Cookie Privacy Policy Here